• Elucidation of the role of connexin proteins in hepatocyte apoptosis

2008-2009: 10.000€

Promoter: Mathieu Vinken

Co-promoter: Vera Rogiers

• Connexin signaling research group (Alliance Research Group)

2011-2020: 10.000€

Promoters: Mathieu Vinken, Luc Leybaert

• Liver-based in vitro models for toxicity testing and translational aspects (Strategic Research Program)

2014-2019: 450.000€

Promoter: Vera Rogiers

Co-promoters: Tamara Vanhaecke, Mathieu Vinken, Jan Gutermuth

• Liver connexin and pannexin research group (Alliance Research Group)

2014-2026: 120.000€

Promoters: Mathieu Vinken, Bruno Cogliati

• Panx1 as a novel biomarker for non-alcoholic steatohepatitis (Industrial Research Fund)

2016-2017: 50.000€

Promoter: Mathieu Vinken

Co-promoter: Serge Muyldermans

• Exploiting peptides: protein binders, modulators and inhibitors for imaging and therapy (Strategic Research Program)

2019-2023: 1.220.000€

Promoter: Steven Ballet

Co-promoters: Vicky Caveliers, Sophie Hernot, Wim Versées, Mathieu Vinken, Serge Muyldermans, Nick Devoogdt

• Non-animal methodologies for toxicity testing of chemical compounds (Interdisciplinary Research Program)

2019-2023: 550.000€

Promoter: Tamara Vanhaecke

Co-promoters: Mathieu Vinken, Joery De Kock, Olga De Troyer, Paul Quinn

• B-liver: The Brussels liver research to valorisation alliance (Groups of Expertise in Applied Research Program)

2020-2024: 650.000€

Promoter: Tamara Vanhaecke

Co-promoters: Leo van Grunsven, Joery De Kock, Mathieu Vinken, Hendrik Reynaert

• Cellular communication as target and biomarker in liver disease and toxicity: from basic research towards clinical application (Methusalem program)

2021-2027: 2.100.000€

Promoter: Mathieu Vinken​

​

• Connexin hemichannels as drug targets in acute liver failure: a combined in vitro-in vivo study

2012-2016: 25.000€

Promoter: Mathieu Vinken

Co-promoters: Tamara Vanhaecke, Vera Rogiers

• Hemichannels as novel pharmacological targets and biomarkers of cholestasis

2017-2020: 25.000€

Promoter: Mathieu Vinken

Co-promoters: Michaël Maes, Bruno Cogliati

• Are connexins, pannexins and their (hemi)channels novel biomarkers and pharmacological targets in the prognosis and therapy of liver cancer?

2020-2023: 22.500€

Promoter: Mathieu Vinken

Co-promoters: Kaat Leroy, Bruno Cogliati

• Can food addities cause liver damage?

2022-2025: 37.500€

Promoter: Mathieu Vinken

     ONTOX: ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemical for next    

     generation risk assessment

2019: 25.000€

Promoter: Mathieu Vinken

​

     HOBOTA: high-dimensional organoid-based organ toxicity assessment

2021-2023: 1.951.707€

Promoter: Freddy Van Goethem

Co-promoters: Mathieu Vinken, Bahar Ramezanpour

​

• Role of Cx32 and Cx43 in the control of hepatocellular homeostasis: development of a long-term primary hepatocyte culture system for pharmaco-toxicological studies

2010-2011: 16.400€

Promoter: Mathieu Vinken

Co-promoter: Vera Rogiers

• Connexin and pannexin channels: regulation, functions and applications

2010-2019: 120.000€

Promoter: Luc Leybaert

Co-promoters: Geert Bultynck, Mathieu Vinken

• Hepatocyte-like cells derived from adult human skin progenitor cells as a potential in vitro model for the screening of drugs for liver toxicity

2013-2016: 160.000€

Promoter: Tamara Vanhaecke

Co-promoters: Mathieu Vinken, Vera Rogiers

• Characterization of Cx43- and Panx1-based hemichannels as tissue biomarkers and pharmacological targets in acute liver failure

2014-2017: 275.236€

Promoter: Mathieu Vinken

Co-promoters: Tamara Vanhaecke, Vera Rogiers

• Hemichannels as novel pharmacological targets in liver fibrosis

2014-2017: 360.000€

Promoter: Mathieu Vinken

Co-promoters: Elke Decrock, Luc Leybaert, Tamara Vanhaecke, Vera Rogiers

• Are connexin and pannexin hemichannels therapeutic drug targets and diagnostic biomarkers in cholestasis?

2018-2021: 425.700€

Promoter: Mathieu Vinken

Co-promoter: Pieter Annaert

• Nanobody-based inhibitors of connexin and pannexin hemichannels as therapeutics for the treatment of hepatic and cardiovascular diseases

2018-2021: 457.700€

Promoter: Mathieu Vinken

Co-promoters: Serge Muyldermans, Brenda Kwak

• Light sheet fluorescence microscope in life sciences and medical research

2018-2022: 689.653,84€

Promoter: Karen Sermon

Co-promoters: Hilde Van De Velde, Ellen Goossens, Luc Baeyens, Jo Van Ginderachter, Dimitri De Bundel, Sophie Hernot, Joery De Kock, Mathieu Vinken, Tamara Vanhaecke, Robim Marcelino Rodrigues, Leo van Grunsven

• Are connexins, pannexins and their (hemi)channels novel biomarkers and pharmacological targets in the prognosis and therapy of liver cancer?

2019-2021: 225.000€ (+ 300.000BRL from São Paulo Research Foundation)

Promoters: Mathieu Vinken, Bruno Cogliati

• Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization system

2020-2023: 342.415,45€

Promoter: Ann Massie

Co-promoters: Eline Menu, Mathieu Vinken, Jo Van Ginderachter, Claudia Spits, Johan Stiens, Rose Njemini, Kenno Vanommeslaeghe

• Modelling and prediction of liver toxicity: focus on drug-induced cholestasis

2021-2025: 62.500€

Promoter: Mathieu Vinken

Co-promoters: Lindsey Devisscher, Pieter Annaert

• Can food additives cause liver damage? A mechanistic in vitro modelling study

2022-2025: 507.000€

Promoter: Mathieu Vinken

Co-promoter: Jochem Louisse​

• The role of pannexin1 channels in non-alcoholic steatohepatitis: therapeutic and diagnostic relevance

2023-2026: 520.000€ (+ 50.000€ for the University of São Paulo)

Promoter: Mathieu Vinken

Co-promoter: Bruno Cogliati